Ardelyx Quarterly Cash Flow Statement
NASDAQ: ARDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.28+0.01 (+0.31%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ardelyx free cash flow
In the quarter ended Jun 30, 2026, Ardelyx generated -$6.4 million of operating cash flow and spent $13,000 on capital expenditures. That left free cash flow of -$6.4 million, a free-cash-flow margin of -5.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Ardelyx cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -16.72M | -37.60M | -407.00K | -969.00K | -19.08M | -41.14M | 4.64M | -809.00K | -16.45M | -26.52M | -28.80M | 6.63M |
| Net Income growth (YoY) | — | — | -108.76% | — | — | — | — | -112.20% | — | — | -369.30% | — |
| Depreciation & Amortization | 604.00K | 915.00K | 921.00K | 905.00K | 631.00K | 602.00K | 515.00K | 544.00K | 569.00K | 435.00K | 362.00K | 291.00K |
| Stock-Based Compensation | 15.32M | 14.16M | 12.45M | 12.74M | 11.69M | 12.09M | 9.86M | 9.13M | 10.77M | 7.62M | 3.93M | 3.49M |
| Change in Working Capital | -6.83M | 4.11M | 10.39M | -16.97M | -27.65M | -1.37M | -8.71M | -7.52M | -12.68M | -24.79M | 17.97M | -29.27M |
| Operating Cash Flow | -6.40M | -32.24M | 20.95M | 365.00K | -25.34M | -38.46M | 9.81M | 501.00K | -19.40M | -35.72M | -8.72M | -21.47M |
| Capital Expenditures | -13.00K | -69.00K | -361.00K | -156.00K | -650.00K | -325.00K | -593.00K | -137.00K | -131.00K | -150.00K | -43.00K | -194.00K |
| Investing Cash Flow | 22.66M | -9.99M | 3.78M | -50.51M | 34.92M | 2.85M | -41.62M | 2.34M | 23.53M | -2.57M | -29.57M | -32.70M |
| Financing Cash Flow | 49.72M | 5.44M | 557.00K | 2.81M | 49.66M | 1.48M | 49.31M | 2.70M | 1.61M | 52.97M | 25.99M | 57.87M |
| Net Change in Cash | 65.98M | -36.79M | 25.28M | -47.33M | 59.24M | -34.12M | 17.50M | 5.54M | 5.74M | 14.68M | -12.30M | 3.71M |
| Free Cash Flow | -6.41M | -32.31M | 20.59M | 209.00K | -25.99M | -38.78M | 9.22M | 364.00K | -19.53M | -35.87M | -8.76M | -21.66M |
This table shows 12 quarterly periods of Ardelyx's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ARDX's reporting calendar. What is a cash flow statement?